apolipoprotein L domain containing 1Genealiases: BDVAS · VERGE
Q-omics provides the consensus-scored APOLD1 profile across patient tissues and cancer cell-line models. APOLD1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, APOLD1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, APOLD1 RNA expression shows 18,937 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where APOLD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for APOLD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes APOLD1 survival associations across molecular data types. APOLD1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible APOLD1 RNA expression–survival associations across cancer types. High APOLD1 expression shows unfavorable associations in KIRP, OV, UVM and UCEC, but favorable associations in KIRC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for APOLD1 RNA expression.
This table summarizes APOLD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for APOLD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. APOLD1 shows lower tumor expression in BLCA, KIRP, LUSC and LUAD and higher tumor expression in KIRC and LIHC. The BLCA box plot shows higher APOLD1 RNA expression in normal versus tumor tissue (log2 FC = −2.115, t-test p < 0.001).
This table shows molecular features associated with APOLD1 in patient tissues and cancer cell lines. In patient samples, APOLD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, APOLD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
